For patients with persistent, recurrent, or metastatic cervical cancer who are receiving chemotherapy with or without bevacizumab, progression-free survival and overall survival are significantly longer with pembrolizumab versus placebo, according to a study published in the New England Journal of Medicine. Nicoletta Colombo, M.D., Ph.D., from the University of Milan-Bicocca and European Institute of Oncology IRCCS,...